TABLE 1.
Baseline Demographics and Clinical Characteristics—Tocilizumab Versus No Tocilizumab
| Variables | Label | Total (n = 118) | Tocilizumab: No (n = 37) | Tocilizumab: Yes (n = 81) | Unadjusted p | S-Weighted p |
|---|---|---|---|---|---|---|
| Age | 58.24 (12.98) | 62.33 (12.89) | 56.32 (12.65) | 0.019 | 0.608 | |
| Gender, n (%) | 0.406 | 0.457 | ||||
| Female | 43 (36.44) | 16 (43.24) | 27 (33.33) | |||
| Male | 75 (63.56) | 21 (56.76) | 54 (66.67) | |||
| Race, n (%) | > 0.999 | 0.902 | ||||
| Non-White | 73 (61.86) | 23 (62.16) | 50 (61.73) | |||
| White | 45 (38.14) | 14 (37.84) | 31 (38.27) | |||
| Comorbidities present, n (%) | 82 (69.49) | 33 (89.19) | 49 (60.49) | 0.003 | 0.357 | |
| Ferritin | 2,049.15 (2,156.77) | 2,001.93 (1,818.25) | 2,072.1 (2,315.15) | 0.875 | 0.968 | |
| d-dimer | 1,207.31 (7,073.24) | 3,679.52 (12,131.76) | 8.66 (9.16) | 0.015 | 0.07 | |
| C-reactive protein | 67.2 (100.53) | 95.62 (106.79) | 55.02 (96.04) | 0.079 | 0.517 | |
| Steroid usage, n (%) | 76 (64.41) | 26 (70.27) | 50 (61.73) | 0.489 | 0.433 | |
| Hydroxychloroquine + azithromycin, n (%) | 116 (98.31) | 37 (100) | 79 (97.53) | > 0.999 | 0.361 | |
| Remdesivir, n (%) | 3 (2.54) | 2 (5.41) | 1 (1.23) | 0.231 | 0.547 |